Midazolam maleate

Buccolam, Midazolam, Midozalam, Nayzilam, Seizalam (midazolam maleate) is a small molecule pharmaceutical. Midazolam maleate was first approved as Versed on 1985-12-20. It is used to treat anxiety disorders, psychomotor agitation, and status epilepticus in the USA. It has been approved in Europe to treat epilepsy.

Download report

Favorite

Events Timeline

Commercial

Clinical

Drug

Target

Variants

Financial

Trends

Safety

Events Timeline

YTD

Max

Events

FDA approval date

EMA approval date

Patent expiration date

Study first post date

Last update post date

Start date

Primary completion date

Completion date

Results first post date

Mock data
Subscribe for the real data

Commercial

Therapeutic Areas

Therapeutic Area	MeSH
nervous system diseases	D009422
signs and symptoms pathological conditions	D013568
behavior and behavior mechanisms	D001520
mental disorders	D001523

Trade Name

FDA

EMA

No data

Drug Products

FDA

EMA

New Drug Application (NDA)

Abbreviated New Drug Application (ANDA)

No data

Labels

FDA

EMA

Brand Name	Status	Last Update
seizalam	New Drug Application	2023-01-26
versed guards up daily mineral sunscreen broad spectrum spf 35	OTC monograph final	2022-08-30
versed spf 30 replenishing body mineral	C200263	2024-12-20

Indications

FDA

EMA

No data

Agency Specific

FDA

EMA

Expiration	Code
MIDAZOLAM, NAYZILAM, UCB INC
2026-05-17	ODE-243
MIDAZOLAM HYDROCHLORIDE, SEIZALAM, MMT
2025-09-14	ODE-207

Patent Expiration

Patent	Expires	Flag	FDA Information
Midazolam, Midazolam In 0.9% Sodium Chloride, Inforlife
10966990	2038-06-20	DP
Midazolam, Nayzilam, Ucb Inc
8217033	2028-01-18	DP	U-2526
8809322	2028-01-18	DP
9289432	2028-01-18	DP	U-2526
9687495	2028-01-18	DP	U-2526

ATC Codes

N: Nervous system drugs

— N05: Psycholeptics

— N05C: Hypnotics and sedatives

— N05CD: Benzodiazepine derivative hypnotics and sedatives

— N05CD08: Midazolam

HCPCS

No data

Clinical

Clinical Trials

1593 clinical trials

View more details

Mock data
Subscribe for the real data

Indications Phases 4

Indication	MeSH	Ontology	ICD-10	Ph 1	Ph 2	Ph 3	Ph 4	Other	Total
Healthy volunteers/patients	—	—	—	193	1	1	2	7	204
Anesthesia	D000758	—	—	4	2	7	19	24	54
Postoperative pain	D010149	—	G89.18	3	6	4	15	28	52
Neoplasms	D009369	—	C80	35	4	2	2	9	49
Delirium	D003693	—	R41.0	6	1	3	15	18	43
Depression	D003863	—	F33.9	9	15	10	7	8	43
Anxiety	D001007	EFO_0005230	F41.1	2	6	2	13	18	40
Depressive disorder	D003866	EFO_1002014	F32.A	8	13	8	8	7	39
Pain	D010146	EFO_0003843	R52	7	3	—	10	13	33
Anxiety disorders	D001008	EFO_0006788	F41.1	2	5	2	10	15	33

Show 273 more

Indications Phases 3

Indication	MeSH	Ontology	ICD-10	Ph 1	Ph 2	Ph 3	Ph 4	Other	Total
Status epilepticus	D013226	EFO_0008526	G41	1	2	9	—	4	15
Post-traumatic stress disorders	D013313	EFO_0001358	F43.1	—	9	3	—	1	11
Atrial fibrillation	D001281	EFO_0000275	I48.0	—	—	1	—	7	8
Traumatic stress disorders	D040921	—	—	—	6	2	—	1	8
Hypoxia	D000860	—	R09.02	—	—	2	—	6	8
Heart arrest	D006323	EFO_0009492	I46	—	—	2	—	5	7
Adenoma	D000236	—	—	—	—	1	—	5	6
Renal insufficiency	D051437	—	N19	3	—	3	—	—	6
Nervous system diseases	D009422	—	G00-G99	1	1	2	—	2	6
Sclerosis	D012598	—	—	3	2	1	—	—	5

Show 71 more

Indications Phases 2

Indication	MeSH	Ontology	ICD-10	Ph 1	Ph 2	Ph 3	Ph 4	Other	Total
Tuberculosis	D014376	EFO_0000774	A15-A19	6	2	—	—	—	7
Atopic dermatitis	D003876	EFO_0000274	L20	5	1	—	—	—	6
Dermatitis	D003872	—	L30.9	5	1	—	—	—	6
Pulmonary tuberculosis	D014397	EFO_1000049	A15	4	2	—	—	—	5
Eczema	D004485	—	L30.9	4	1	—	—	—	5
Carcinoma	D002277	—	C80.0	2	1	—	—	2	4
Operative surgical procedures	D013514	—	—	—	2	—	—	2	4
Leukemia	D007938	—	C95	4	3	—	—	—	4
Myeloid leukemia acute	D015470	—	C92.0	4	3	—	—	—	4
Myeloid leukemia	D007951	—	C92	4	3	—	—	—	4

Show 60 more

Indications Phases 1

Indication	MeSH	Ontology	ICD-10	Ph 1	Ph 2	Ph 3	Ph 4	Other	Total
Drug interactions	D004347	—	—	29	—	—	—	3	32
Psoriasis	D011565	EFO_0000676	L40	11	—	—	—	—	11
Arthritis	D001168	EFO_0005856	M05-M14	6	—	—	—	1	7
Overweight	D050177	—	E66.3	6	—	—	—	—	6
Rheumatoid arthritis	D001172	EFO_0000685	M06.9	6	—	—	—	—	6
Colorectal neoplasms	D015179	—	—	1	—	—	—	4	5
Sickle cell anemia	D000755	EFO_0000697	D57	4	—	—	—	1	5
Melanoma	D008545	—	—	4	—	—	—	—	4
Food-drug interactions	D018565	—	—	3	—	—	—	1	4
Hepatitis c	D006526	—	B19.2	4	—	—	—	—	4

Show 113 more

Indications Without Phase

Indication	MeSH	Ontology	ICD-10	Ph 1	Ph 2	Ph 3	Ph 4	Other	Total
Cardiopulmonary bypass	D002315	—	—	—	—	—	—	4	4
Aging	D000375	GO_0007568	R41.81	—	—	—	—	3	3
Tachycardia	D013610	—	R00.0	—	—	—	—	3	3
Airway management	D058109	—	—	—	—	—	—	3	3
Epidural analgesia	D015360	—	—	—	—	—	—	2	2
Aortic dissection	D000784	—	I71.0	—	—	—	—	2	2
Thoracic surgical procedures	D019616	—	—	—	—	—	—	2	2
Anterograde amnesia	D020324	—	R41.1	—	—	—	—	2	2
Intraoperative awareness	D058926	—	—	—	—	—	—	2	2
Gastrointestinal microbiome	D000069196	—	—	—	—	—	—	2	2

Show 178 more

Epidemiology

Epidemiological information for investigational and approved indications

View more details

Drug

General

Drug common name	Midazolam maleate
INN	midazolam
Description	Midazolam is an imidazobenzodiazepine that is 4H-imidazo[1,5-a][1,4]benzodiazepine which is substituted by a methyl, 2-fluorophenyl and chloro groups at positions 1, 6 and 8, respectively. It has a role as a GABAA receptor agonist, an anticonvulsant, an anxiolytic drug, an apoptosis inducer, an antineoplastic agent, a muscle relaxant, a sedative, a general anaesthetic and a central nervous system depressant. It is an organochlorine compound, an imidazobenzodiazepine and a member of monofluorobenzenes.
Classification	Small molecule
Drug class	Benzodiazepine
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)	Cc1ncc2n1-c1ccc(Cl)cc1C(c1ccccc1F)=NC2.O=C(O)/C=C\C(=O)O